- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04698343
Noninvasive Peripheral Nerve Stimulation for Restless Legs Syndrome During Opioid Medication Reduction
June 27, 2023 updated by: Noctrix Health, Inc.
Exploratory Study Assessing the Response of Restless Legs Syndrome (RLS) Patients to Non-invasive Peripheral Nerve Stimulation (NPNS) During Opioid Medication Reduction
Prospective open-label single-arm feasibility study assessing the tolerability of opioid medication reduction in conjunction with noninvasive peripheral nerve stimulation (NPNS) for patients taking prescription opioids to treat moderate-severe primary RLS.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
For RLS patients taking a stable dose of prescription opioid medications prior to study entry, iterative opioid dose reduction is performed in conjunction with open-label NPNS treatment.
For each of two iterative step-downs in opioid dose (step-down #1 and step-down #2), a 1-2-week run-in phase to allow resolution of opioid withdrawal symptoms unrelated to RLS is followed by a 1-wk assessment phase to evaluate if RLS symptoms have increased.
Study participation is terminated if there is a clinically significant increase in RLS severity during the assessment phase or if there are intolerable opioid withdrawal symptoms at any time.
Participants who tolerate both step-downs have the option of an extension phase involving a third step-down with the same format.
Study Type
Interventional
Enrollment (Actual)
21
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Downey, California, United States, 90241
- Mark J Buchfuhrer private practice
-
-
Ohio
-
Dublin, Ohio, United States, 43017
- Ohio Sleep Medicine Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 89 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Subject has received a medical diagnosis of primary restless legs syndrome (RLS)
- Subject is currently taking a stable dose of at least one prescription opioid for RLS, where the total opioid dose is less than or equal to 60mg morphine milligram equivalents (MME) per day.
- RLS symptoms are most significant in the subject's legs and/or feet.
- Subject possesses the necessary equipment, internet/phone accessibility, and communication ability to complete electronic questionnaires and respond to electronic communications and phone calls from the research staff throughout the in-home portion of the study.
- Subject is 18 to 89 years of age (inclusive) when written informed consent is obtained.
- Subject has signed a valid, Institutional Review Board (IRB)-approved informed consent form, can understand the requirements of the study and instructions for device usage, and can converse in English.
- Subject has been taking a stable dose and schedule of prescription opioids for RLS for at least 3 months prior to enrollment.
Exclusion Criteria:
- Subject has RLS that is known to be caused by another diagnosed condition (i.e. secondary RLS).
- Subject was misdiagnosed with RLS, as determined by the investigator (e.g. actual diagnosis of Periodic Leg Movement Disorder (PLMD), arthritis, leg spasms or neuropathy without comorbid RLS).
- Subject has primary sleep disorder other than RLS that significantly interferes with sleep at the present time (e.g. unmanaged sleep apnea or general insomnia).
- Subject has been diagnosed with one of the following conditions at any time: Epilepsy or other seizure disorder, Severe movement disorder symptoms (Parkinson's disease, Huntington's disease, dyskinesia, dystonia), Deep Vein Thrombosis, Multiple sclerosis
- Subject has an active diagnosis of one of the following conditions: Acute or chronic infection other than viral upper respiratory tract infections, Stage 4-5 chronic kidney disease or renal failure, Iron-deficient anemia, Severe edema affecting lower legs
- Subject has any of the following at the location of device application: Acute injury, Cellulitis, Open sores
- Subject has a malignancy within the past 5 years (not including basal or squamous cell skin cancer)
- Subject is on dialysis or anticipated to start dialysis while participating in the study
- Subject has severe peripheral neuropathy affecting the lower legs and/or subject has neuropathy and is unable to clearly distinguish between symptoms of neuropathy and symptoms of RLS.
- During NPNS calibration, subject has a sensation threshold above the upper-cutoff value (e.g. 30mA), the subject finds stimulation intensities less than 15 mA to be uncomfortable or distracting, or the device does not properly fit the subject.
- Subject has significantly changed dose or schedule of a medication that may impact RLS symptoms within the 30 days prior to enrollment, as judged by the investigator (e.g. antidepressants, sleep medications, sedative antihistamines).
- Subject has received an investigational drug or device within the last 30 days or is planning to receive an investigational device during the duration of the study.
- Subject has another medical condition that may affect validity of the study as determined by the investigator.
- Subject is unable or unwilling to comply with study requirements.
- Moderate or severe cognitive disorder or mental illness.
- Subject has prior experience with Noctrix Health NPNS devices.
- Subject has active implantable medical devices anywhere in the body (including pacemakers), or metal implant at the site of study device electrode application.
- Subject has known allergy to electrode gel, polyurethane foam, or lycra.
- Subject is pregnant or trying to become pregnant.
- Subject has undergone a major surgery (excluding dental work) in the previous 30 days.
- Subject has another medical condition that may put the subject at risk as determined by the investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Noninvasive Peripheral Nerve Stimulation (NPNS)
NPNS device programmed to deliver active stimulation.
|
NPNS device programmed to deliver active stimulation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Opioid reduction tolerability rate during step-down #1 as measured by Clinical Global Impression - Improvement (CGI-I) scale
Time Frame: 1 week assessment period for step-down #1 compared to 1 week baseline period
|
Percentage of subjects without a clinically significant increase in RLS symptoms (i.e.
CGI-I score of 5 or less relative to baseline) during the first Phase involving an opioid dose reduction of >= 20% relative to baseline.
|
1 week assessment period for step-down #1 compared to 1 week baseline period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Opioid reduction tolerability rate during step-down #2 as measured by Clinical Global Impression - Improvement (CGI-I) scale
Time Frame: 1 week assessment period for step-down #2 compared to 1 week baseline period
|
Percentage of subjects without a clinically significant increase in RLS symptoms (i.e.
CGI-I score of 5 or less relative to baseline) during the first Phase involving an opioid dose reduction of >= 1/3 relative to baseline
|
1 week assessment period for step-down #2 compared to 1 week baseline period
|
Change from baseline in International Restless Legs Syndrome Study Group Rating Scale (IRLS) score during step-down #1
Time Frame: 1 week assessment period for step-down #1 compared to 1 week baseline period
|
IRLS is a participant-rated questionnaire that rates RLS severity from 0-40, where 40 is the most severe.
|
1 week assessment period for step-down #1 compared to 1 week baseline period
|
Change from baseline in IRLS score during step-down #2
Time Frame: 1 week assessment period for step-down #2 compared to 1 week baseline period
|
IRLS is a participant-rated questionnaire that rates RLS severity from 0-40, where 40 is the most severe.
|
1 week assessment period for step-down #2 compared to 1 week baseline period
|
Maximal tolerated reduction in opioid dose
Time Frame: Time Frame: 1 week assessment period for final step-down compared to 1 week baseline period
|
Maximal percentage reduction in opioid dose relative to baseline associated with a CGI-I score of 5 or less, averaged across subjects.
|
Time Frame: 1 week assessment period for final step-down compared to 1 week baseline period
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
NPNS tolerability rate
Time Frame: Full duration of NPNS usage through study completion, up to 9 weeks
|
Percentage of subjects who withdraw from study prior to the Extension Phase citing lack of tolerability of NPNS as the primary reason for withdrawal.
|
Full duration of NPNS usage through study completion, up to 9 weeks
|
Frequency of Grade 2 or higher NPNS-related adverse events.
Time Frame: Full duration of NPNS usage through study completion, up to 9 weeks
|
Frequency of Grade 2 or higher NPNS-related adverse events.
|
Full duration of NPNS usage through study completion, up to 9 weeks
|
Frequency of Grade 3 or higher NPNS-related adverse events.
Time Frame: Full duration of NPNS usage through study completion, up to 9 weeks
|
Frequency of Grade 3 or higher NPNS-related adverse events.
|
Full duration of NPNS usage through study completion, up to 9 weeks
|
NPNS compliance during step-down #1
Time Frame: 1 week assessment period for step-down #1
|
Frequency of device usage during assessment period during step-down #1
|
1 week assessment period for step-down #1
|
NPNS compliance during step-down #2
Time Frame: 1 week assessment period for step-down #2
|
Frequency of device usage during assessment period during step-down #2
|
1 week assessment period for step-down #2
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Jonathan D Charlesworth, PhD, Noctrix Health, Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 6, 2021
Primary Completion (Actual)
February 27, 2023
Study Completion (Actual)
March 28, 2023
Study Registration Dates
First Submitted
January 4, 2021
First Submitted That Met QC Criteria
January 5, 2021
First Posted (Actual)
January 6, 2021
Study Record Updates
Last Update Posted (Actual)
June 29, 2023
Last Update Submitted That Met QC Criteria
June 27, 2023
Last Verified
June 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CT-03
- R44NS117294 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Restless Legs Syndrome
-
Walter Reed National Military Medical CenterWithdrawnEkbom Syndrome | Restless Legs Syndrome, | Restless Legs,United States
-
GlaxoSmithKlineCompletedRestless Legs Syndrome | Restless Legs Syndrome (RLS)United States
-
Otsuka Pharmaceutical Co., Ltd.CompletedIdiopathic Restless Legs Syndrome
-
XenoPort, Inc.CompletedRestless Legs Syndrome (RLS)United States
-
American Regent, Inc.CompletedRestless Legs Syndrome (RLS)United States
-
Astellas Pharma IncCompletedRestless Legs Syndrome (RLS)Japan
-
Otsuka Pharmaceutical Co., Ltd.CompletedIdiopathic Restless Legs SyndromeJapan
-
UCB PharmaCompletedIdiopathic Restless Legs SyndromeGermany
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedIdiopathic Restless Legs SyndromeUnited States, Spain, Finland, Italy, Germany, Sweden, Austria, Netherlands, United Kingdom
-
American Regent, Inc.CompletedRestless Legs Syndrome (RLS)
Clinical Trials on Noninvasive Peripheral Nerve Stimulation (NPNS)
-
University of LjubljanaUniversity Medical Centre LjubljanaCompletedParkinson Disease | Neurologic DisorderSlovenia
-
University of ArkansasStanford UniversityCompleted
-
University Medical Centre LjubljanaCompletedParkinson Disease | Gait Disorders, NeurologicSlovenia
-
MetroHealth Medical CenterEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompleted
-
Hospital Israelita Albert EinsteinFundação de Amparo à Pesquisa do Estado de São PauloRecruiting
-
MetroHealth Medical CenterUniversity of TexasActive, not recruitingShoulder Impingement Syndrome | Shoulder Pain | Pain, Shoulder | Shoulder Bursitis | Shoulder TendinitisUnited States
-
University of California, San DiegoCopenhagen University Hospital at Herlev; University California Academic Senate and other collaboratorsCompletedPostoperative PainUnited States
-
Epineuron Technologies Inc.RecruitingNerve InjuryCanada, United States
-
Laval UniversityUnknownTobacco Use DisorderCanada
-
MetroHealth Medical CenterEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsActive, not recruiting